ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ATXS Astria Therapeutics Inc

9.10
-0.07 (-0.76%)
Last Updated: 02:27:00
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Astria Therapeutics Inc ATXS NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
-0.07 -0.76% 9.10 02:27:00
Open Price Low Price High Price Close Price Previous Close
9.18 8.99 9.46 9.17
more quote information »

Recent News

Date Time Source Heading
09/4/202422:00BWAstria Therapeutics Appoints Sunil Agarwal to Its Board of..
04/4/202407:10BWAstria Therapeutics Announces Inducement Grants Under Nasdaq..
25/3/202422:30BWAstria Therapeutics Announces Positive Initial..
06/3/202408:10BWAstria Therapeutics Announces Inducement Grants Under Nasdaq..
05/3/202409:22EDGAR2Form 8-K - Current report
05/3/202409:20EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
05/3/202408:10BWAstria Therapeutics Reports Fourth Quarter and Full Year..
05/3/202408:02EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
21/2/202400:00BWAstria Therapeutics to Present at Upcoming American Academy..
15/2/202407:48EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
15/2/202407:00EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
15/2/202400:36EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
13/2/202408:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202408:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202408:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202408:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202408:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202408:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/2/202400:00BWAstria Therapeutics to Present at Upcoming Oppenheimer 34th..
06/2/202408:00BWAstria Therapeutics Announces Inducement Grants Under Nasdaq..
01/2/202401:00EDGAR2Form 8-K - Current report
01/2/202400:59EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
31/1/202409:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/1/202401:08BWAstria Therapeutics Announces Pricing of $125 Million..
30/1/202422:01EDGAR2Form 8-K - Current report
30/1/202408:39EDGAR2Form 144 - Report of proposed sale of securities
17/1/202408:18EDGAR2Form SC 13G - Statement of acquisition of beneficial..
06/1/202400:30EDGAR2Form 8-K - Current report
03/1/202408:16EDGAR2Form SC 13G - Statement of acquisition of beneficial..
02/1/202416:15EDGAR2Form EFFECT - Notice of Effectiveness
29/12/202306:09EDGAR2Form S-3/A - Registration statement under Securities Act of..
21/12/202308:30EDGAR2Form 8-K - Current report
16/12/202300:30EDGAR2Form S-3 - Registration statement under Securities Act of..
05/12/202308:00BWAstria Therapeutics Announces Inducement Grants Under Nasdaq..
28/11/202300:00BWAstria Therapeutics to Present STAR-0215 Data at the 2023..
22/11/202300:00BWAstria Therapeutics to Present at Upcoming 6th Annual..
14/11/202308:02EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/11/202300:06EDGAR2Form 8-K - Current report
14/11/202300:00BWAstria Therapeutics Reports Third Quarter Financial Results..
11/11/202300:00BWAstria Therapeutics Presents New Phase 1a Data Confirming..
10/11/202300:00BWAstria Therapeutics to Present at Upcoming Jefferies London..
03/11/202323:10BWAstria Therapeutics to Present New STAR-0215 Data at the..
03/11/202307:00BWAstria Therapeutics Announces Inducement Grants Under Nasdaq..
30/10/202323:00BWAstria Therapeutics to Report Third Quarter 2023 Financial..
13/10/202308:04EDGAR2Form 8-K - Current report
13/10/202308:01EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
12/10/202323:00EDGAR2Form 8-K - Current report
12/10/202310:14BWAstria Therapeutics Announces Pricing of $64 Million..
12/10/202308:14EDGAR2Form 8-K - Current report
12/10/202308:10BWAstria Therapeutics Announces Exclusive Worldwide License..

Your Recent History

Delayed Upgrade Clock